How Acquiring Sponsors Can Keep Post-Acquisition Clinical Operations Running Smoothly

By Leila Cupersmith, Founder and CEO, Choice ClinOps

Acquisitions are typically evaluated through the lens of strategic fit, pipeline expansion, platform access, and long-term value creation. In clinical development, however, they create a second and far more immediate test of leadership: whether the acquiring sponsor can preserve operational continuity across active trials while integrating new assets, teams, technologies, vendors, and decision structures.

For acquiring sponsors, the post-acquisition risk is rarely the transaction itself. The greater risk is what happens after close, when integration activity begins to pressure live clinical programs that cannot pause. Enrollment continues. Sites continue operating. Data continue flowing. Patients and caregivers continue depending on consistent execution. Yet this is also the exact period when reporting lines shift, systems are reassessed, budget ownership changes, vendor relationships are reevaluated, and organizational priorities compete for attention.

That is where value can begin to leak.

For CEOs and presidents, this is a pipeline value protection issue. If operational disruption slows execution, weakens milestones, or erodes confidence in inherited assets, the deal begins losing value before leadership has fully realized its intended upside. For CFOs, this is an avoidable burn issue. Delayed decisions, duplicated effort, vendor confusion, and unstable operating models create unnecessary spending at a moment when capital discipline should be strongest. For COOs, this is an execution-control issue. If integration introduces ambiguity faster than the organization restores clarity, operational instability follows. For heads and VPs of clinical operations, this is a sponsor-side visibility, governance, and continuity issue across active studies that cannot afford drift.

This deserves far more executive attention than it often receives.

Clinical trials do not wait for integration to settle. They continue moving through start-up, enrollment, treatment, monitoring, data review, and milestone execution while the organization around them is changing. In oncology, rare disease, and gene therapy, that pressure is even more consequential. These programs often involve compressed development timelines, complex protocols, specialized vendors, sensitive data flows, limited patient populations, intricate manufacturing or chain-of-custody dependencies, and very little tolerance for execution inconsistency. In those environments, even modest disruption can have outsized effects on start-up timelines, enrollment continuity, protocol adherence, data quality, inspection readiness, and site confidence.

The central question for acquiring sponsors is therefore not whether integration will create change. It will. The more important question is whether the sponsor has a strong enough sponsor-side operating model to absorb that change without destabilizing active programs.

Four Disruptive Post-Acquisition Patterns To Watch For

In practice, post-acquisition disruption tends to emerge through a small number of recurring patterns. Here are four disruptive post-acquisition patterns that successful acquiring sponsors proactively plan for and manage.

The first is loss of operational clarity. Once legacy and acquiring teams are combined, study teams are often no longer certain who owns key decisions, who has authority to direct external partners, which risks require escalation, or how priorities should be balanced across inherited and existing programs. When that happens, decision latency increases at exactly the moment when speed and clarity matter most.

The second is fragmentation across CROs, vendors, laboratories, and sites. After an acquisition, external partners frequently continue executing against the previous sponsor’s assumptions while the acquiring sponsor’s priorities, decision rights, timelines, and risk tolerance have already shifted. Without rapid re-anchoring to one sponsor-side operating rhythm, one escalation pathway, and one shared set of priorities, execution drift begins to appear across functions, geographies, and milestones. This shows up as siloed work, delayed escalations, outdated reporting, misaligned vendor activity, inconsistent site communication, data transfer gaps, budget leakage, and milestone slippage.

The third is technology-induced instability. Acquisitions often bring new systems, data environments, digital tools, biomarker platforms, reporting structures, or operational technologies that appear strategically attractive. But when technology integration moves faster than process alignment, role clarity, or execution readiness, the result is usually more friction, not more control. New systems do not create continuity by themselves. They must sit inside an operating model that preserves accountability, workflow reliability, and data integrity under pressure.

The fourth is workforce discontinuity. This risk is routinely underestimated. Critical trial knowledge is often held by individuals, not only by governance decks, trackers, or transition plans. Site history, vendor realities, protocol-specific sensitivities, regional nuances, and informal escalation logic are frequently more fragile than leadership assumes. When that knowledge is lost before it is intentionally transferred, execution quality can deteriorate faster than formal structures suggest.

These are not theoretical concerns. They are the predictable points at which acquiring sponsors begin to lose control if continuity is not managed as a sponsor-side priority from the outset.

That is why post-acquisition clinical operations continuity should not be treated as a downstream integration workstream. It should be treated as an executive-level sponsor-side control function, with clear ownership before close and disciplined stabilization immediately after.

Planning Starts Before The Contract Is Signed

The acquiring sponsors that protect value most effectively usually begin before the contract is fully executed. Pre-close continuity planning should move beyond broad integration mapping and focus on identifying where operational fragility is most likely to surface first. Not every study carries the same continuity risk. Early-phase dose-escalation trials, global Phase 3 studies nearing critical milestones, rare disease protocols dependent on limited site networks, and gene therapy programs with complex manufacturing interfaces require different protections and different leadership attention. The issue is not simply what is being acquired. It is which active programs are most vulnerable to disruption once integration pressure begins.

This is also the stage when accountability must start becoming explicit. If ownership of study-level decisions, vendor direction, risk acceptance, and escalation remains ambiguous at close, the sponsor creates avoidable delay precisely when decisive control is most valuable. One of the earliest continuity advantages is operational clarity established early enough to prevent drift from taking hold.

The First 90 Days Are Crucial

From Day 1 through Day 90, the leadership priority should be controlled stabilization. This is the period to preserve execution continuity while integration moves in a deliberate sequence. The sponsors that do this well typically move quickly to reset decision rights, reestablish sponsor-side visibility across external partners, protect milestone-critical workflows, maintain data accountability through transition, and preserve access to essential trial knowledge before avoidable attrition or confusion compromises execution.

That work sounds straightforward on paper. In reality, it is where many acquiring sponsors begin to lose momentum.

Most post-acquisition disruption does not begin with one dramatic breakdown. It begins with a series of manageable-looking discontinuities across decisions, systems, teams, vendors, and data flows. A delayed escalation here. Misaligned vendor execution there. A role handoff that looks complete but is not. A governance forum that produces reporting without resolution. A technology transition that advances faster than operating readiness. Each issue may look containable in isolation. Collectively, they weaken control.

This is also the point at which many organizations overestimate the protective value of high-level integration oversight. Integration dashboards and executive forums matter, but they do not by themselves preserve trial continuity. Live programs require sponsor-side operational leadership close enough to execution to detect weakening control before it becomes visible in milestones, data quality, site confidence, or workforce stability.

Integrated Sponsor-Side Partners Can Add Disproportionate Value

The most effective continuity efforts are not driven by generic integration theory or broad activity by the centralized governing study portfolio group. They are driven by disciplined sponsor-side operational leadership close enough to live programs to distinguish between ordinary transition noise and signals of meaningful instability. That requires recognizing where governance has weakened, where decisions are stalling, where vendors are drifting, where data flow risk is increasing, where workforce discontinuity may become execution risk, and where intervention must happen early to prevent damage to milestones, inspection readiness, or patient and site experience.

In my experience planning for, governing, and leading sponsor-side post-acquisition continuity across complex clinical development environments, the highest-risk periods are often the ones that appear manageable from a distance. That is why continuity cannot be governed effectively through high-level integration oversight alone. It requires sponsor-side operational judgment embedded close enough to the work to identify loss of control before it becomes visible in trial outcomes.

Fractional executive clinical operations leadership can be especially effective in this window because it allows the acquiring sponsor to strengthen control quickly without waiting for permanent organizational redesign, lengthy hiring cycles, or additional internal strain on already stretched teams. Used well, this model provides experienced sponsor-side leadership across governance, escalation, integrated partner alignment, milestone protection, and transition execution during the period when the cost of delay is often highest and the room for error is narrowest.

Realizing Post-Acquisition Value Means Recognizing Risks Early

Acquiring a pipeline, platform, or capability may create strategic opportunity. Preserving the operating conditions that allow that value to be realized is a separate leadership task, and one that becomes visible very quickly in live clinical development.

The sponsors that navigate acquisitions most effectively are typically the ones that treat clinical operations continuity as an executive discipline from the outset. They do not wait for milestone slippage, budget variance, partner drift, or workforce disruption to tell them where control has weakened. They establish clarity early, stabilize decisively, and remain close enough to execution to see risk while it is still manageable.

For leaders preparing for or actively integrating an acquisition, the important question is no longer whether change is coming. It is whether the organization has put the right sponsor-side controls around its most vulnerable active programs before that change begins to dilute execution.

In active trials, continuity is not a secondary integration objective. It is part of how acquired value is protected, realized, and sustained.

About The Author:

Leila Cupersmith is founder and CEO of Choice ClinOps, a sponsor-side fractional and embedded clinical operations command center for small and mid-size oncology, rare disease, and cell and gene therapy sponsors. Choice ClinOps is not a CRO; it works inside the sponsor’s operating model as a senior execution-control layer across CROs, vendors, laboratories, sites, and internal teams. With more than 20 years of global Phase 1–3 clinical operations experience, Leila and her team help sponsors rescue delayed studies, strengthen governance, re-anchor external partners, and protect continuity through M&A, licensing, and CRO transitions.